Quoin Pharmaceuticals (NASDAQ:QNRX) Issues Earnings Results, Misses Estimates By $0.35 EPS

Quoin Pharmaceuticals (NASDAQ:QNRX) posted its earnings results on Thursday. The company reported ($6.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.36) by ($0.35), Zacks reports.

Quoin Pharmaceuticals Trading Up 5.1%

QNRX stock traded up $0.44 during trading hours on Friday, hitting $9.01. 44,442 shares of the stock traded hands, compared to its average volume of 222,841. Quoin Pharmaceuticals has a one year low of $5.01 and a one year high of $48.30. The company has a market cap of $5.30 million, a P/E ratio of -0.22 and a beta of 1.72. The stock has a 50-day simple moving average of $9.85 and a 200 day simple moving average of $8.61.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Insider Buying and Selling at Quoin Pharmaceuticals

In other news, Director Dennis Langer purchased 15,152 shares of Quoin Pharmaceuticals stock in a transaction that occurred on Tuesday, October 14th. The stock was acquired at an average price of $8.49 per share, for a total transaction of $128,640.48. Following the transaction, the director owned 15,153 shares in the company, valued at $128,648.97. The trade was a 1,515,200.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 13.46% of the stock is owned by company insiders.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.